(2R)-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid | 883888-21-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (2R)-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
• 英文别名: Unii-96RH6Z678D
• CAS: 883888-21-9
• 化学式: C₁₂H₆F₆O₄
• 分子量: 328.168
• InChiKey: CSOISVJKLBMNCK-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid 生成 (2R)-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
  参考文献：
  名称：

  [EN] SUBSTITUTED CYCLOPROPYL CHROMENE COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFLAMMATION RELATED CONDITIONS
  [FR] COMPOSES DE CYCLOPROPYL CHROMENE SUBSTITUES DESTINES A ETRE UTILISES DANS LE TRAITEMENT ET LA PREVENTION DE PATHOLOGIES LIEES A DES INFLAMMATIONS

  摘要：

  本发明涉及在与环氧合酶-2介导的疾病相关的情况治疗中具有效用的方法和化合物。特别感兴趣的化合物是由式（1）定义的苯并吡喃和它们的类似物，其中Z、X、R1、R2、R3和R4如规范中所述。

  公开号：

  WO2006040672A1

文献信息

• THERAPEUTIC FORMULATIONS AND USES THEREOF
  申请人：Piedmont Animal Health Inc.

  公开号：EP3664800A1

  公开（公告）日：2020-06-17
• LONG-ACTING INJECTABLE FORMULATIONS AND USE THEREOF
  申请人：Piedmont Animal Health Inc.

  公开号：EP3975994A1

  公开（公告）日：2022-04-06
• [EN] THERAPEUTIC FORMULATIONS AND USES THEREOF<br/>[FR] FORMULATIONS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：PIEDMONT ANIMAL HEALTH LLC

  公开号：WO2019032910A1

  公开（公告）日：2019-02-14

  Provided herein are pharmaceutically acceptable compositions containing a selective cyclooxygenase-2 (COX-2) inhibitor (coxib) and optionally buprenorphine. In particular, compositions containing a coxib formulated for oral, topical or subcutaneous administration to treat pain or inflammation are described.
• [EN] LONG-ACTING INJECTABLE FORMULATIONS AND USE THEREOF<br/>[FR] FORMULATIONS INJECTABLES À LIBÉRATION PROLONGÉE ET LEUR UTILISATION
  申请人：PIEDMONT ANIMAL HEALTH INC

  公开号：WO2020242862A1

  公开（公告）日：2020-12-03

  Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection. In various embodiments, the pharmaceutically acceptable composition is a sterile injectable liquid that once injected subcutaneously increases in viscosity thereby forming an in-situ forming depot (ISFD) which provides sustained release of the pharmaceutically active agent. The ISFD is formed by a depot forming agent that precipitates and entraps the pharmaceutically active agent upon subcutaneous injection.
• [EN] SUBSTITUTED CYCLOPROPYL CHROMENE COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFLAMMATION RELATED CONDITIONS<br/>[FR] COMPOSES DE CYCLOPROPYL CHROMENE SUBSTITUES DESTINES A ETRE UTILISES DANS LE TRAITEMENT ET LA PREVENTION DE PATHOLOGIES LIEES A DES INFLAMMATIONS
  申请人：PHARMACIA & UPJOHN CO LLC

  公开号：WO2006040672A1

  公开（公告）日：2006-04-20

  The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (1) Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.

  本发明涉及在与环氧合酶-2介导的疾病相关的情况治疗中具有效用的方法和化合物。特别感兴趣的化合物是由式（1）定义的苯并吡喃和它们的类似物，其中Z、X、R1、R2、R3和R4如规范中所述。